Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Abercrombie & Fitch Co. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.72 (market cap $5.07B), while Abercrombie & Fitch Co. trades at $113.11 (market cap $5.24B). The key difference: ACADIA Pharmaceuticals Inc. and Abercrombie & Fitch Co. are close in size by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ACAD | ANF | |
|---|---|---|
Market Cap | $5.07B | $5.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $129.85 |
52-Week Low | $20.06 | $65.61 |
Enterprise Value | $4.19B | $5.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
ANF trades at $114.45, down 3.44% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong fundamentals with a P/E of 11.41, net income margin of 9.34%, and three consecutive quarterly EPS beats. Revenue grew to $4.95 billion in 2025, up from $4.3 billion in 2024, while operating cash flow reached $710.38 million. Recent news highlights institutional buying and an upcoming Q2 2026 earnings report on August 26, 2026.
Outlook is mixed: valuation metrics appear attractive, and earnings momentum supports upside, but overbought RSI levels and competitive retail headwinds pose risks. Analyst consensus is a $112.86 price target with 35.71% buy ratings, suggesting cautious optimism amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
